Tina Guanting Qiu, MD PhD, EMBA

Tina Guanting Qiu, MD, PhD, EMBA, is a visionary biotech entrepreneur, retinal surgeon, and stem cell transplant biologist with over 25 years of experience in ophthalmology and more than 16 years of global leadership in therapeutic innovation. As the Founder and CEO of Ophthalmic Therapeutic Innovation (OTI), she spearheads the development of OTI-2024, a patented, dual-action therapy targeting both intraocular pressure and neural protection for glaucoma. Her work is aimed at delivering the first curative eye drop for treating glaucoma neural degeneration and refractory glaucoma, leveraging a robust 20-year intellectual property estate, Phase 2 clinical data, and a de-risked regulatory pathway under the FDA’s 505(b)(2) designation. Tina has also guided strategic out-licensing of sustained-release implant IP assets to industry leaders in ocular drug delivery.

Throughout her career, Tina has collaborated with biotech CEOs, boards, CSOs, and pharma partners to shape regulatory frameworks, develop high-value delivery platforms, and navigate first-in-class programs through clinical and commercial inflection points. Her advisory and leadership contributions include setting FDA precedents in retinal gene therapy, designing sustained-release ophthalmic portfolios, and pioneering clinic-to-bench drug discovery programs. Notably, her guidance on Lineage Cell Therapeutics’ OpRegen program contributed to the successful $670M Roche-Lineage deal in 2021. She has also led critical strategic initiatives during the COVID-19 pandemic, influencing global treatment strategies through her work on inhaled therapeutics and clinical trial design.

Dr. Qiu earned her MD with honors from Nanchang University and completed a PhD in Clinical Ophthalmology at Zhongshan Ophthalmic Center, affiliated with National Sun Yat-sen University and the University of Pennsylvania, focusing on stem cell transplant and retinal regenerative medicine. She completed postdoctoral training at Boston University and USC’s Doheny Eye Institute and is an elected member of the American Academy of Ophthalmology. Tina’s work has earned her multiple accolades, including the IAOTP Top Physician Entrepreneur and Innovator of the Year Award, and she continues to advance ophthalmic science and biotech innovation while mentoring the next generation of leaders in the field.

• Sun Yat-sen University - PhD

• M&A: Making The Deal
• Corporate Governance
• Developing Business Plan
• English Business Formation Law
• Business Story Telling
• Data Collection
• Art of Negotiation
• Microeconomics
• Certificate of US Business Law
• Honored Listee
• Content Strategy for Professionals: Engaging Audiences for Your Organization
• Retina Research Fellow/Guest Research Physician
• Ophthalmology Board Certificate
• Elected Member of American Academy of Ophthalmology

• Dr. Tina Guanting Qiu selected for The Empowered Woman Award by IAOTP
• Top Physician Entrepreneur and Innovator of the Year by IAOTP
• Albert Nelson Marquis Lifetime Achievement Award- 2023
• Maquis Who's Who Humanitarian Award-2021
• Marquis Who's Who for Excellence in Ophthalmology 2021
• 2013 AAO Virtual Meeting Points Leader Award (1st Place)
• GSK Bronze Award for Leading Sustained-relese Ocular Drug Delivery Innovation

• Northshore Technology Council, Mass
• The Association for Women in Science (AWIS)
• Senior Executive Networking Group- New England (SENG-NE)
• New England Healthcare Executive Network (NEHEN)
• America Academy of Ophthalmology

• Medical Development Group of Boston
• MassChallenge
• Harvard Business School (HBS)
• NorthShore Technology Council
• McKinsey & Company

Dr. Guanting Qiu has contributed extensively to the field of ophthalmology, with a focus on retinal therapeutics, regenerative medicine, and innovative ocular drug delivery strategies. Her key publications include:

Trabodenoson on Trabecular Meshwork Rejuvenation: A Comprehensive Review of Clinical Data, Expert Opinion on Investigational Drugs, March 27, 2021.

Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells (MA09-hRPE) in Macular Degeneration, npj Regenerative Medicine, August 27, 2019.

Retinal Progenitor Cells, UK Patent Application, July 28, 2019.

Method of Reprogramming Adult Retinal Cells into Photoreceptor Progenitors, UK Patent Application Numbers #0913109.5 (July 28, 2009) and #0914999.8 (August 28, 2009), prepared by UK Patent Attorney Rhinnanon Turner, PhD.

CyPass Withdrawal Root Cause Insight and Risk Mitigation Strategy: From Procedure-Based Medicine to Biology-Based Medicine, EC Ophthalmology, December 9, 2018.

Unique Insight of Retina Gene Therapy, EC Ophthalmology, January 9, 2018.

Defining the Problem for Ophthalmic Drug Development & Clinical Translation, EC Ophthalmology, April 1, 2016.

New Frontiers of Retinal Therapeutic Innovation & Strategic Insights, EC Ophthalmology, September 5, 2015; recognized as "Best Paper of the Issue."

Revisit Rescula and Cystoid Macular Edema and Refractory Glaucoma, Journal of Clinical & Experimental Ophthalmology, September 1, 2015.

New Frontiers of Therapeutic Intervention for Retina, YouTube publication, July 1, 2015.

Ocriplasmin & Muller Glia, Advances in Ophthalmology & Visual System/MedCrave, August 4, 2014.

An Evolving Paradigm of Ocular Therapeutic Strategy and Delivery Technology Innovation, MassBio, Cambridge, MA (speaker), October 17, 2012.

A New Model of Experimental Subretinal Neovascularization in the Rabbit (Patented), Experimental Eye Research, March 1, 2006; Provisional Patent Application No. 60407(50420), November 2003–November 2005 (Inventor with Jay M. Stewart and Eugene de Juan Jr.).

Artificial Vision, in Surgery of Macular Diseases, People’s Medical Publishing House, China, Chapter 29, Pages 381–383, January 1, 2005.

Development, Implantation, In Vivo Elution, and Retrieval of a Biocompatible, Sustained-Release Subretinal Drug Delivery System, Journal of Biomedical Materials Research Part A, November 21, 2005.

Photoreceptor Differentiation and Integration of Retinal Progenitor Cells Transplanted into Transgenic Rats, Experimental Eye Research, 80(4):515–525, 2005.

Natural History of Asymptomatic Clinical Retinal Detachments, American Journal of Ophthalmology, 2005.

A Pilot Study of Bone Marrow Stromal Cells Intraocular Transplantation in S334 Transgenic Rats and Sprague-Dawley Rats, Eye Sciences, 2002.

The Mechanism of Increasing Outflow Facility During Washout in the Bovine Eye, Investigative Ophthalmology & Visual Science, 43(11):3455–3464, 2002.

Clinical Investigation of Radiation Retinopathy – Fundus and Fluorescein Angiographic Features, Eye Sciences, 1999(4):182–186.

Review: Photoreceptor Apoptosis and Neural Protection, Foreign Medicine, Ophthalmology, 3:561–565 (In Chinese), 1999.

The Prospect of Gene Therapy on Retinal Degenerative Diseases (Review), Chinese Journal of Ocular Fundus Diseases, 4:268–270, 1999.

A Retrospective Study of Combined Anterior Capsule-Preserved Lensectomy and Pars Plana Vitrectomy for Cataract and Severe Vitreoretinal Diseases.

Dr. Qiu’s work reflects a deep commitment to advancing retinal science through both clinical research and innovative therapeutic development.